About this Journal Submit a Manuscript Table of Contents
ISRN Pharmacology
Volume 2012 (2012), Article ID 984786, 6 pages
http://dx.doi.org/10.5402/2012/984786
Review Article

Biomarkers in Alzheimer's Disease: A Review

1Department of Clinical Pharmacy, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Vile Parle, Mumbai 400056, India
2Department of Pharmacology, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Vile Parle, Mumbai 400056, India

Received 3 April 2012; Accepted 20 May 2012

Academic Editors: R. Couture and M. Tohda

Copyright © 2012 Meena Chintamaneni and Manju Bhaskar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Duff and F. Suleman, “Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development?” Briefings in Functional Genomics & Proteomics, vol. 3, no. 1, pp. 47–59, 2004. View at Scopus
  2. Y. H. Suh and F. Checler, “Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease,” Pharmacological Reviews, vol. 54, no. 3, pp. 469–525, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. K. N. Prasad, W. C. Cole, and K. C. Prasad, “Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment,” Journal of the American College of Nutrition, vol. 21, no. 6, pp. 506–522, 2002. View at Scopus
  4. A. H. Simonsen, J. McGuire, O. Hansson et al., “Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment,” Archives of Neurology, vol. 64, no. 3, pp. 366–370, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Humpel and T. Hochstrasser, “Cerebrospinal fluid and blood biomarkers in Alzheimer's disease,” World Journal of Psychiatry, vol. 1, no. 1, pp. 8–18, 2011. View at Publisher · View at Google Scholar
  6. B. L. Tang and R. Kumar, “Biomarkers of mild cognitive impairment and Alzheimer's disease,” Annals of the Academy of Medicine Singapore, vol. 37, no. 5, pp. 406–410, 2008. View at Scopus
  7. N. Mattsson and H. Zetterberg, “Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications,” Biomarkers in Medicine, vol. 3, no. 6, pp. 735–737, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. I. Dominguez, D. Hartmann, and B. De Strooper, “BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease,” Neurodegenerative Diseases, vol. 1, no. 4-5, pp. 168–174, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Shoffner, M. D. Brown, A. Torroni et al., “Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients,” Genomics, vol. 17, no. 1, pp. 171–184, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. G. E. Gibson, V. Haroutunian, H. Zhang et al., “Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype,” Annals of Neurology, vol. 297, pp. 297–303, 2000.
  11. M. S. Wolfe, “Gamma-scretase-intramembrane protease with a complex,” Science of Aging Knowledge Environment, vol. 2003, no. 11, article E7, 2003.
  12. R. E. Tanzi and L. Bertram, “Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective,” Cell, vol. 120, no. 4, pp. 545–555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. L. F. Lau, J. B. Schachter, P. A. Seymour, and M. A. Sanner, “Tau protein phosphorylation as a therapeutic target in Alzheimer's disease,” Current Topics in Medicinal Chemistry, vol. 2, no. 4, pp. 395–415, 2002. View at Scopus
  14. J. B. Martin, “Molecular basis of the neurodegenerative disorders,” The New England Journal of Medicine, vol. 340, no. 25, pp. 1970–1980, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. S. M. Lopez, L. Morelli, E. M. Castano, and J. M. Pasquini, “Defective ubiquitination of cerebral proteins in Alzheimer's disease,” Journal of Neuroscience Research, vol. 62, pp. 302–310, 2000. View at Publisher · View at Google Scholar
  16. F. Checler, C. Alves Da Costa, K. Ancolio, N. Chevallier, E. Lopez-Perez, and P. Marambaud, “Role of the proteasome in Alzheimer's disease,” Biochimica et Biophysica Acta, vol. 1502, no. 1, pp. 133–138, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. T. J. Montine, K. S. Montine, W. McMahan, W. R. Markesbery, J. F. Quinn, and J. D. Morrow, “F2-isoprostanes in Alzheimer and other neurodegenerative diseases,” Antioxidants and Redox Signaling, vol. 7, no. 1-2, pp. 269–275, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. Refolo, M. A. Pappolla, B. Malester et al., “Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model,” Neurobiology of Disease, vol. 7, no. 4, pp. 321–331, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. R. E. Mrak and W. S. T. Griffin, “Potential Inflammatory biomarkers in Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 8, no. 4, pp. 369–375, 2005. View at Scopus
  20. E. R. Peskind, W. S. T. Griffin, K. T. Akama, M. A. Raskind, and L. J. Van Eldik, “Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease,” Neurochemistry International, vol. 39, no. 5-6, pp. 409–413, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. J. D. Luterman, V. Haroutunian, S. Yemul et al., “Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia,” Archives of Neurology, vol. 57, no. 8, pp. 1153–1160, 2000. View at Scopus
  22. T. Kordula, R. E. Rydel, E. F. Brigham, F. Horn, P. C. Heinrich, and J. Travis, “Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate α1-antichymotrypsin expression in human cortical astrocytes,” The Journal of Biological Chemistry, vol. 273, no. 7, pp. 4112–4118, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. G. M. Murphy Jr., L. Yang, and B. Cordell, “Macrophage colony-stimulating factor augments β-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells,” The Journal of Biological Chemistry, vol. 273, no. 33, pp. 20967–20971, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. S. D. Yan, H. Zhu, J. Fu et al., “Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 5296–5301, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. T. K. Khan and D. L. Alkon, “An internally controlled peripheral biomarker for Alzheimer's disease: Erk1 and Erk2 responses to the inflammatory signal bradykinin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 13203–13207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Galimberti, N. Schoonenboom, P. Scheltens et al., “Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease,” Archives of Neurology, vol. 63, no. 4, pp. 538–543, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Q. Zhao, L. Ravindranath, A. S. Mohamed et al., “MAP kinase signaling cascade dysfunction specific to Alzheimer's disease in fibroblasts,” Neurobiology of Disease, vol. 11, no. 1, pp. 166–183, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Blasko, K. Jellinger, G. Kemmler et al., “Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid-β 42, medial temporal lobe atrophy and homocysteine,” Neurobiology of Aging, vol. 29, no. 1, pp. 1–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. P. D. Mehta, T. Pirttilä, S. P. Mehta, E. A. Sersen, P. S. Aisen, and H. M. Wisniewski, “Plasma and cerebrospinal fluid levels of amyloid β proteins 1–40 and 1–42 in Alzheimer disease,” Archives of Neurology, vol. 57, no. 1, pp. 100–105, 2000. View at Scopus
  30. R. Mayeux, L. S. Honig, M. X. Tang et al., “Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk,” Neurology, vol. 61, no. 9, pp. 1185–1190, 2003. View at Scopus
  31. H. Fukumoto, M. Tennis, J. J. Locascio, B. T. Hyman, J. H. Growdon, and M. C. Irizarry, “Age but not diagnosis is the main predictor of plasma amyloid β-protein levels,” Archives of Neurology, vol. 60, no. 7, pp. 958–964, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Borroni, M. Di Luca, and A. Padovani, “Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?” European Journal of Pharmacology, vol. 545, no. 1, pp. 73–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. C. Irizarry, “Biomarkers of Alzheimer disease in plasma,” NeuroRx, vol. 1, no. 2, pp. 226–234, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. H. Freeman, S. Raju, B. T. Hyman, M. P. Frosch, and M. C. Irizarry, “Plasma Aβ levels do not reflect brain Aβ levels,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 4, pp. 264–271, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. van Oijen, A. Hofman, H. D. Soares, P. J. Koudstaal, and M. M. Breteler, “Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study,” The Lancet Neurology, vol. 5, no. 8, pp. 655–660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Pesaresi, C. Lovati, P. Bertora et al., “Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment,” Neurobiology of Aging, vol. 27, no. 6, pp. 904–905, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. N. R. Graff-Radford, J. E. Crook, J. Lucas et al., “Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease,” Archives of Neurology, vol. 64, no. 3, pp. 354–362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Oprisiu, J. M. Serot, O. Godefroy, S. E. Black, and A. Fournier, “Plasma amyloid-β concentrations in Alzheimer's disease: an alternative hypothesis,” The Lancet Neurology, vol. 5, no. 12, pp. 1001–1002, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Chabas, S. E. Baranzini, D. Mitchell et al., “The influence of the proinflammatory cytokine, osteopontin, on autoimmue demyelinating desease,” Science, vol. 294, no. 5547, pp. 1731–1735, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Valk, F. Barkhof, and P. Scheltens, Magnetic Resonance in Dementia, Springer, Heidelberg, Germany, 2002.
  41. M. Albert, C. De Carli, and S. De Kosky, “The use of MRI and PET for clinical diagnosis of dementia and investigation of cognitive impairment,” A consensus report, Report of the neuroimaging work group of the Alzheimer's Association, 2005.
  42. H. V. Vinters, Z. Z. Wang, and D. L. Secor, “Brain parenchymal and microvascular amyloid in Alzheimer's disease,” Brain Pathology, vol. 6, no. 2, pp. 179–195, 1996. View at Scopus
  43. A. Nordberg, “PET imaging of amyloid in Alzheimer's disease,” The Lancet Neurology, vol. 3, no. 9, pp. 519–527, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. B. J. Bacskai, G. A. Hickey, J. Skoch et al., “Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12462–12467, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. S. B. Raymond, J. Skoch, I. D. Hills, E. E. Nesterov, T. M. Swager, and B. J. Bacskai, “Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, supplement 1, pp. S93–S98, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. M. A. Yassa, “Searching for novel biomarkers using high resolution diffusion tensor imaging,” in Handbook of Imaging the Alzheimer Brain, pp. 547–555, ISO Press, 2011.
  47. O. Rukovets, “FDA approves florbetapir for imaging amyloid beta for Alzheimer's disease,” Neurology Today, vol. 12, no. 10, pp. 18–20, 2012.